A recent study highlighted the vital role of GSK3β in TAMs, since GSK3β deficiency in macrophage can restrict HCC progression by inhibiting M2 phenotype and enhancing the sensitivity of anti-PD-1 immunotherapy (130). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.